Bills › 91st General Assembly
Relating to the controlled substance crystalline polymorph psilocybin
Where it is now
- Done: IntroducedJanuary 14, 2025
- Done: SubcommitteeFebruary 24, 2025
- Done: Senate committeeFebruary 13, 2025
- Done: Passes the SenateApril 16, 202547–0
- Skipped: House committeeSkipped
- Done: Passes the HouseFebruary 20, 202592–0
- Done: To the GovernorMay 19, 2025
- Stopped: VetoedJune 11, 2025
Died when the session ended The 2026 session adjourned on May 3, 2026, the General Assembly’s last regular session. Bills that didn’t pass both chambers died. What’s a funnel?
What’s in it
AI summary If the FDA approves a specific form of the drug psilocybin, this law would move it from a highly restricted category to a different one. Once this change happens, doctors could legally prescribe and sell the drug. This would change how the substance is treated under state law.1
Read the official explanation
This bill relates to the controlled substance crystalline polymorph psilocybin.201(4)(s)).204(4), a drug that contains the pharmaceutical composition of crystalline polymorph psilocybin shall be immediately removed from schedule I upon its approval by the United States food and drug administration and rescheduled based upon the recommendations of the United States food and drug administration and its listing in the federal Controlled Substances Act. _____ it shall be lawful to prescribe, distribute, and market the pharmaceutical composition of crystalline polymorph psilocybin. Current penalties for the possession of psilocybin range from a serious misdemeanor to a class “B” felony.
Senate subcommittee
Named February 24, 2025. It hasn’t reported yet.
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part
Family tree
Study bill
91st General Assembly